Enliven Therapeutics, Inc. (ELVN)
Data as of , from SEC Form 4 filings.
See up to 3 months of ELVN. The 7-day demo opens the 1M and 3M ranges and puts ELVN on your watchlist.
Start 7-day demoLatest ELVN insider trades
- J. Scott Garland - DirectorOpen-market sale$607K
About Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
- BURLINGAME, CA
- 67
- 2023
- XNAS
https://www.enliventherapeutics.comSEC filings for ELVN on EDGAR
ELVN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 22 | 204,849 | $11.95M |
| Option exercise | 20 | 383,698 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ELVN insider transactions (Form 4)
10086 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| J. Scott Garland - Director | Option exercise | Common Stock | 13,000 | $15.47 | $201K | |
| J. Scott Garland - Director | Open-market sale | Common Stock | 13,000 | $46.67 footnote F1 | $607K | |
| J. Scott Garland - Director | Option exercise | Stock Option (right to buy) | 13,000 | $0.00 | - | |
| ||||||
| Benjamin Hohl - Officer | Option exercise | Common Stock | 3,982 | $14.85 | $59K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 3,535 | $50.03 footnote F3 | $177K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 2,194 | $50.72 footnote F4 | $111K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 289 | $51.49 footnote F5 | $15K | |
| Benjamin Hohl - Officer | Option exercise | Stock Option (right to buy) | 3,982 | $0.00 | - | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 5,000 | $2.48 | $12K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 2,916 | $50.03 footnote F3 | $146K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 1,844 | $50.71 footnote F4 | $94K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 240 | $51.48 footnote F5 | $12K | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| ||||||
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 4,630 | $58.35 footnote F2 | $270K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 1,388 | $59.35 footnote F4 | $82K | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 5,000 | $2.48 | $12K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 3,900 | $58.37 footnote F3 | $228K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 1,100 | $59.35 footnote F4 | $65K | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| ||||||
 Mika K. Derynck - Director | Option exercise | Common Stock | 87,373 | $2.48 | $217K | |
| Mika K. Derynck - Director | Option exercise | Common Stock | 27,567 | $25.28 | $697K | |
| Mika K. Derynck - Director | Option exercise | Common Stock | 23,364 | $14.85 | $347K | |
| Mika K. Derynck - Director | Option exercise | Common Stock | 20,491 | $22.47 | $460K | |
| Mika K. Derynck - Director | Open-market sale | Common Stock | 158,795 | $60.21 footnote F2 | $9.56M | |
| Mika K. Derynck - Director | Option exercise | Stock Option (right to buy) | 87,373 | $0.00 | - | |
| Mika K. Derynck - Director | Option exercise | Stock Option (right to buy) | 27,567 | $0.00 | - | |
| Mika K. Derynck - Director | Option exercise | Stock Option (right to buy) | 23,364 | $0.00 | - | |
| Mika K. Derynck - Director | Option exercise | Stock Option (right to buy) | 20,491 | $0.00 | - | |
| ||||||
| Benjamin Hohl - Officer | Option exercise | Common Stock | 1,072 | $2.48 | $3K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 324 | $49.97 footnote F3 | $16K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 369 | $51.48 footnote F4 | $19K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 2,564 | $52.32 footnote F5 | $134K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 2,638 | $53.38 footnote F6 | $141K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 123 | $53.87 footnote F7 | $7K | |
| Benjamin Hohl - Officer | Option exercise | Stock Option (right to buy) | 1,072 | $0.00 | - | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 5,000 | $2.48 | $12K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 231 | $50.05 footnote F3 | $12K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 459 | $51.55 footnote F4 | $24K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 2,063 | $52.39 footnote F5 | $108K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 2,184 | $53.42 footnote F6 | $117K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 63 | $53.92 footnote F7 | $3K | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| ||||||
| Lori Anne Kunkel | Open-market sale | Common Stock | 4,111 | $49.98 footnote F2 | $205K | |
| Lori Anne Kunkel | Open-market sale | Common Stock | 5,889 | $50.84 footnote F3 | $299K | |
| ||||||
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 46,776 | $45.00 | $2.10M | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 24,846 | $45.38 | $1.13M | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 1,477 | $45.00 | $66K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 787,024 | $45.38 | $35.72M | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 1,238 | $44.75 footnote F5 | $55K | |
| Benjamin Hohl - Officer | Option exercise | Stock Option (right to buy) | 6,018 | $0.00 | - | |
| Benjamin Hohl - Officer | Option exercise | Common Stock | 6,018 | $2.48 | $15K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 1,379 | $42.79 footnote F3 | $59K | |
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 3,401 | $43.86 footnote F4 | $149K | |
| ||||||
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 1,268 | $42.83 footnote F3 | $54K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 2,599 | $43.87 footnote F4 | $114K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 1,133 | $44.74 footnote F5 | $51K | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Helen Louise Collins - Officer | Option exercise | Common Stock | 5,000 | $2.48 | $12K | |
| ||||||
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 9,086 | $45.02 | $409K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 272,322 | $45.02 | $12.26M | |
| Lori Anne Kunkel | Open-market sale | Common Stock | 7,779 | $34.28 footnote F2 | $267K | |
| Lori Anne Kunkel | Open-market sale | Common Stock | 1,867 | $35.36 footnote F4 | $66K | |
| Lori Anne Kunkel | Open-market sale | Common Stock | 354 | $35.82 footnote F5 | $13K | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 5,000 | $2.48 | $12K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 3,475 | $39.53 footnote F3 | $137K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 1,302 | $40.25 footnote F4 | $52K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 223 | $41.21 footnote F5 | $9K | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 5,000 | $2.48 | $12K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 140 | $45.81 footnote F3 | $6K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 2,419 | $47.39 footnote F4 | $115K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 2,441 | $48.06 footnote F5 | $117K | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 40,000 | $2.48 | $99K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 40,000 | $35.10 footnote F3 | $1.40M | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 40,000 | $0.00 | - | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 5,000 | $2.48 | $12K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 5,000 | $27.76 footnote F3 | $139K | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 29,871 | $2.48 | $74K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 29,871 | $30.02 footnote F3 | $897K | |
| Helen Louise Collins - Officer | Option exercise | Common Stock | 10,129 | $2.48 | $25K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 10,129 | $30.19 footnote F5 | $306K | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 29,871 | $0.00 | - | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 10,129 | $0.00 | - | |
| ||||||
| Benjamin Hohl - Officer | Open-market sale | Common Stock | 10,000 | $29.58 footnote F1 | $296K | |
| ||||||
 Richard A. Heyman | Open-market sale | Common Stock | 1,230 | $26.18 footnote F2 | $32K | |
| ||||||
| Helen Louise Collins - Officer | Option exercise | Common Stock | 45,000 | $2.48 | $112K | |
| Helen Louise Collins - Officer | Open-market sale | Common Stock | 45,000 | $26.17 footnote F2 | $1.18M | |
| Helen Louise Collins - Officer | Option exercise | Stock Option (right to buy) | 45,000 | $0.00 | - | |
| ||||||
| Lori Anne Kunkel | Grant or award | Stock Option (right to buy) | 17,126 | $0.00 | - | |
| Richard A. Heyman | Grant or award | Stock Option (right to buy) | 19,234 | $0.00 | - | |
| Rishi Gupta | Grant or award | Stock Option (right to buy) | 33,989 | $0.00 | - | |
| Rishi Gupta | Grant or award | Stock Option (right to buy) | 1,580 | $0.00 | - | |
| J. Scott Garland | Grant or award | Stock Option (right to buy) | 1,427 | $0.00 | - | |
| Mika K. Derynck | Grant or award | Stock Option (right to buy) | 17,126 | $0.00 | - | |
| Jake Bauer | Grant or award | Stock Option (right to buy) | 17,126 | $0.00 | - | |
 Rahul D. Ballal | Grant or award | Stock Option (right to buy) | 17,126 | $0.00 | - | |
 Anish Patel - Officer | Grant or award | Common Stock | 20,000 footnote F1 | $0.00 | - | |
| Anish Patel - Officer | Grant or award | Stock Option (right to buy) | 120,000 | $0.00 | - | |
| ||||||
Item 2.02, 9.01
Item 1.01, 7.01, 9.01
Item 7.01, 8.01, 9.01
Item 5.03, 5.07, 9.01
Recent ELVN Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| JEFFREY GARLAND | Director | 13,000 | $607K | View on EDGAR | |
| Hohl Benjamin | Officer | 12,036 |
ELVN insider trading FAQ
What is the latest insider trade for ELVN?
Enliven Therapeutics, Inc. (ELVN) had 8 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for ELVN runs to 86 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ELVN stock?
No insider purchases of ELVN were filed in the last 90 days.
How many insiders are selling ELVN stock?
22 insider sales of ELVN were filed in the last 90 days, totaling $11.95M.
Where can I see ELVN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ELVN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - J. Scott Garland view on EDGAR
- - Benjamin Hohl view on EDGAR
- - Helen Louise Collins view on EDGAR
- - Benjamin Hohl view on EDGAR
- - Helen Louise Collins view on EDGAR
- - Mika K. Derynck view on EDGAR
- - Benjamin Hohl view on EDGAR
- - Helen Louise Collins view on EDGAR
- - Lori Anne Kunkel view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ELVN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ELVN with a 7-day demo
- ELVN on your watchlist
- Every ELVN Form 4 filing on record
- Up to 3 months of ELVN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
